ECU
ABBV icon

Egerton Capital (UK)’s AbbVie ABBV Stock Holding History

Egerton Capital (UK)’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-3,899,611
Closed -$255M – 36
2014
Q4 		$255M Buy
+3,899,611
New +$246M 3.42% 13

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Egerton Capital (UK)'s ABBV Position: Q1 2015 in Review

Egerton Capital (UK) sold out of AbbVie (ABBV) in Q1 2015, closing a stake of 3,899,611 shares — an estimated $255M sold.

Egerton Capital (UK) first reported a position in ABBV in Q4 2014 and held it in 1 quarter. The position peaked at $255M in Q4 2014. 1,600 funds tracked by Wall St. Rank hold ABBV as of Q1 2015.

  • Egerton Capital (UK) reported no remaining AbbVie position as of Q1 2015 after selling out during the quarter.
  • Egerton Capital (UK) sold 3,899,611 AbbVie shares in Q1 2015, an estimated $255M.
  • Egerton Capital (UK) first reported a position in AbbVie in Q4 2014 and held it in 1 quarter.
  • Egerton Capital (UK)'s AbbVie position peaked at $255M in Q4 2014.
  • 1,600 funds tracked by Wall St. Rank held AbbVie as of Q1 2015.

Based on Egerton Capital (UK)'s 13F filing for Q1 2015, filed 11 May 2015.